A Trial of Patients With a Charles Bonnet Syndrome (CBS)
Primary Purpose
Prevalence, Psychiatrist Intervention
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
interview
Sponsored by
About this trial
This is an interventional treatment trial for Prevalence, Psychiatrist Intervention focused on measuring Randomized control trial, Charles Bonnet syndrome, visual hallucinations, age related macular degeneration, patient education
Eligibility Criteria
Inclusion Criteria:
- written informed consent
- visual acuity of 0.5 LogMAR or less at both eyes
- 55 years or older
Patients with CBS:
- have no mental pathologies such as dementia, psychosis or any other neurological diseases
- have a normal cognitive state
- are not able to control the VH
- know that the VH are not real
- are usually older
- have significantly reduced visual acuity due to an bilateral eye pathology
VH associated with CBS:
- disappear when the eyes are closed
- are repetitive
- are complex (eg. objects, geometrical patterns, faces, shapes, figures, scenes, animals or plants)
Exclusion Criteria:
- dopamine agonist medication
- temporal lobe epilepsy
- moderate to severe Alzheimer's dementia
- present chronic alcohol-/drug abuse
- bad cognitive state
There are no:
- auditory or olfactory hallucinations
- other abnormalities like delusions
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
interview with an ophthalmologist
interview/treatment by a psychiatrist
Arm Description
Patients get an interview with an ophthalmologist
patients get an interview and a possible treatment by a psychiatrist
Outcomes
Primary Outcome Measures
Quality of life score between the two groups
Quality of life score between the study and control group
Secondary Outcome Measures
Full Information
NCT ID
NCT03148249
First Posted
February 9, 2017
Last Updated
June 26, 2017
Sponsor
Vienna Institute for Research in Ocular Surgery
1. Study Identification
Unique Protocol Identification Number
NCT03148249
Brief Title
A Trial of Patients With a Charles Bonnet Syndrome
Acronym
CBS
Official Title
A Randomized Control Trial of Patients With a Charles Bonnet Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
October 10, 2014 (Actual)
Primary Completion Date
February 17, 2016 (Actual)
Study Completion Date
February 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Charles Bonnet Syndrome (CBS) is defined by the occurence of visual hallucinations (VH) in the absence of any mental disorder. Elderly patients with reduced visual acuity due to ophthalmic diseases are most affected. Conditions are often associated with the syndrome of age-related macular degeneration, cataract or glaucoma. Existing data on the syndrome's prevalence in Europe reveal diverse results. Aim of this study was to assess the prevalence of CBS in patients with low visual acuity and to evaluate, if an additional therapeutic interview with and treatment by a psychiatrist is beneficial.
Detailed Description
Patients with a visual acuity of 0.5 LogMAR or less in the better eye were screened for CBS. Instruments used were an interview asking for details of the hallucinations, a mental test and a scale concerning quality of life. Patients with CBS were randomized by minimization in two groups: in group 1, a patient-doctor interview by an ophthalmologist was performed and in group 2 an interview and if needed, a therapy by a psychiatrist. At the 3-months follow up, the psychological strain of patients was recorded again.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prevalence, Psychiatrist Intervention
Keywords
Randomized control trial, Charles Bonnet syndrome, visual hallucinations, age related macular degeneration, patient education
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
interview with an ophthalmologist
Arm Type
Experimental
Arm Description
Patients get an interview with an ophthalmologist
Arm Title
interview/treatment by a psychiatrist
Arm Type
Experimental
Arm Description
patients get an interview and a possible treatment by a psychiatrist
Intervention Type
Other
Intervention Name(s)
interview
Intervention Description
control group: interview, study group: explanation and exploration
Primary Outcome Measure Information:
Title
Quality of life score between the two groups
Description
Quality of life score between the study and control group
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
written informed consent
visual acuity of 0.5 LogMAR or less at both eyes
55 years or older
Patients with CBS:
have no mental pathologies such as dementia, psychosis or any other neurological diseases
have a normal cognitive state
are not able to control the VH
know that the VH are not real
are usually older
have significantly reduced visual acuity due to an bilateral eye pathology
VH associated with CBS:
disappear when the eyes are closed
are repetitive
are complex (eg. objects, geometrical patterns, faces, shapes, figures, scenes, animals or plants)
Exclusion Criteria:
dopamine agonist medication
temporal lobe epilepsy
moderate to severe Alzheimer's dementia
present chronic alcohol-/drug abuse
bad cognitive state
There are no:
auditory or olfactory hallucinations
other abnormalities like delusions
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Trial of Patients With a Charles Bonnet Syndrome
We'll reach out to this number within 24 hrs